NextTrip (NTRP) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 12, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38015
Entity Registrant Name	SIGMA ADDITIVE SOLUTIONS, INC.
Entity Central Index Key	0000788611
Entity Tax Identification Number	27-1865814
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3900 Paseo del Sol
Entity Address, City or Town	Santa Fe
Entity Address, State or Province	NM
Entity Address, Postal Zip Code	87507
City Area Code	(505)
Local Phone Number	438-2576
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SASI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity common stock shares outstanding		10,772,713

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 1,488,704	$ 2,845,931
Accounts Receivable, net	210,449	371,620
Inventory	944,402	950,943
Prepaid Assets	235,003	105,226
Total Current Assets	2,878,558	4,273,720
Other Assets:
Property and Equipment, net	284,193	304,903
Intangible Assets, net	1,165,558	1,125,285
Total Other Assets	1,449,751	1,430,188
TOTAL ASSETS	4,328,309	5,703,908
Current Liabilities:
Accounts Payable	400,640	277,492
Deferred Revenue	153,443	120,073
Accrued Expenses	219,126	231,633
Total Current Liabilities	773,209	629,198
TOTAL LIABILITIES	773,209	629,198
Commitments & Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 316 and 465 shares issued and outstanding, respectively	1	1
Common Stock, $0.001 par value; 24,000,000 shares authorized; 10,772,713 and 10,498,802 shares issued and outstanding, respectively	10,773	10,499
Additional Paid-In Capital	54,749,821	54,406,694
Accumulated Deficit	(51,205,495)	(49,342,484)
Total Stockholders’ Equity	3,555,100	5,074,710
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 4,328,309	$ 5,703,908

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	316	465
Preferred stock, shares outstanding	316	465
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	24,000,000	24,000,000
Common stock, shares issued	10,772,713	10,498,802
Common stock, shares outstanding	10,772,713	10,498,802

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
REVENUES	$ 130,159	$ 51,844
COST OF REVENUE	63,664	40,091
GROSS PROFIT	66,495	11,753
OPERATING EXPENSES:
Salaries & Benefits	931,583	1,292,010
Stock-Based Compensation	224,850	170,976
Operations and R&D Costs	126,712	143,418
Investor, Public Relations and Marketing	54,944	94,326
Organization Costs	51,198	58,749
Legal & Professional Service Fees	184,251	211,416
Office Expenses	154,499	205,432
Depreciation & Amortization	28,127	31,584
Other Operating Expenses	91,980	87,787
Total Operating Expenses	1,848,144	2,295,698
LOSS FROM OPERATIONS	(1,781,649)	(2,283,945)
OTHER INCOME (EXPENSE)
Interest Income	8	1,571
State Incentives		76,628
Exchange Rate Loss	(2,503)	(330)
Interest Expense	(3,235)	(1,319)
Other Income	35,680
Total Other Income	29,950	76,550
LOSS BEFORE PROVISION FOR INCOME TAXES	(1,751,699)	(2,207,395)
Provision for income Taxes
Net Loss	(1,751,699)	(2,207,395)
Preferred Dividends	(11,748)	(14,220)
Net Loss Applicable to Common Stockholders	$ (1,763,447)	$ (2,221,615)
Net Loss per Common Share – Basic and Diluted	$ (0.17)	$ (0.21)
Weighted Average Number of Shares Outstanding – Basic and Diluted	10,690,677	10,498,802

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1	$ 10,499	$ 53,442,431	$ (40,593,180)	$ 12,859,751
Beginning balance, shares at Dec. 31, 2021	465	10,498,802
Net Loss				(2,207,395)	(2,207,395)
Preferred Stock Dividends			14,220	(14,220)
Stock Options Issued to Directors for Services			21,721		21,721
Stock Options Issued for Third Party Services			(11,713)		(11,713)
Stock Options Issued to Employees			170,976		170,976
Stock Options Issued for Third Party Services			11,713		11,713
Ending balance, value at Mar. 31, 2022	$ 1	$ 10,499	53,661,061	(42,814,795)	10,856,766
Ending balance, shares at Mar. 31, 2022	465	10,498,802
Beginning balance, value at Dec. 31, 2022	$ 1	$ 10,499	54,406,694	(49,342,484)	5,074,710
Beginning balance, shares at Dec. 31, 2022	465	10,498,802
Net Loss				(1,751,699)	(1,751,699)
Preferred Stock Dividends		$ 44	11,704	(11,748)
Preferred stock dividend, shares		43,896
Common Shares Issued for Conversion of Preferred Stock		$ 230	(230)
Common Shares Issued for Conversion of Preferred Shares, shares	(149)	230,015
Common Warrant Issued for Conversion of Preferred Stock			99,564	(99,564)
Stock Options Issued to Directors for Services			7,728		7,728
Stock Options Issued for Third Party Services			(489)		(489)
Stock Options Issued to Employees			224,850		224,850
Stock Options Issued for Third Party Services			489		489
Ending balance, value at Mar. 31, 2023	$ 1	$ 10,773	$ 54,749,821	$ (51,205,495)	$ 3,555,100
Ending balance, shares at Mar. 31, 2023	316	10,772,713

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
OPERATING ACTIVITIES
Net Loss	$ (1,751,699)	$ (2,207,395)
Noncash Expenses:
Depreciation and Amortization	28,127	31,584
Stock-Based Compensation
Change in Assets and Liabilities:
Accounts Receivable	161,171	151,170
Inventory	6,541	(72,019)
Prepaid Assets	(129,777)	(50,996)
Accounts Payable	123,148	114,105
Deferred Revenue	33,370	11,421
Accrued Expenses	(12,507)	(209,299)
NET CASH USED IN OPERATING ACTIVITIES	(1,309,537)	(2,027,019)
INVESTING ACTIVITIES
Purchase of Property and Equipment		(83,248)
Purchase of Intangible Assets	(47,690)	(58,851)
NET CASH USED IN INVESTING ACTIVITIES	(47,690)	(142,099)
FINANCING ACTIVITIES
NET CASH PROVIDED BY FINANCING ACTIVITIES
NET CHANGE IN CASH FOR PERIOD	(1,357,227)	(2,169,118)
CASH AT BEGINNING OF PERIOD	2,845,931	11,447,047
CASH AT END OF PERIOD	1,488,704	9,277,929
Noncash Investing and Financing Activities Disclosure:
Preferred Stock Dividends	11,748	14,220
Conversion of Preferred Shares to Common Shares	188,830
Other Noncash Operating Activities Disclosure:
Issuance of Securities for services	7,239	33,434
Disclosure of Cash Paid for:
Interest	3,235	1,319
Income Taxes
Employees [Member]
Noncash Expenses:
Stock-Based Compensation	224,850	170,976
ThirdParty Services [Member]
Noncash Expenses:
Stock-Based Compensation	(489)	11,713
Director [Member]
Noncash Expenses:
Stock-Based Compensation	$ 7,728	$ 21,721

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 - Summary of Significant Accounting Policies Nature of Business Basis of Presentation Going Concern The Company currently has sufficient cash and working capital to fund operations through June 2023 and will require additional funding in the public or private markets in the near-term to be able to continue operations. The Company currently has no understanding or agreement to obtain such funding, and there is no assurance that we will be successful in obtaining additional funding. If we fail to obtain sufficient funding when needed, we will be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations. As a result, there is substantial doubt about our ability to continue as a going concern. Fair Value of Financial Instruments The Company does not use derivative instruments for hedging market risk or for trading or speculative purposes. Loss Per Share Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 March 31, 2023 2022 Warrants 5,314,175 3,825,781 Stock Options 2,062,659 1,547,797 Preferred Stock 58,568 148,918 Total Underlying Common Shares 7,435,402 5,522,496 The following table shows the amounts used in computing loss per share and the effect on net loss and the weighted average number of shares of dilutive potential common stock for the periods ended March 31, 2023 and 2022: Schedule of Computing Loss Per Share 2023 2022 Three Months Ended March 31 2023 2022 Net Loss per Common Share - Basic and Diluted $ (0.17 ) $ (0.21 ) Loss Applicable to Common Stockholders (numerator) $ (1,763,447 ) $ (2,221,615 ) Weighted Average Number of Common Shares Outstanding Used in Loss Per Share During the Period (denominator) 10,690,677 10,498,802 Accounting Estimates Leases Long-Lived and Intangible Assets Revenue Recognition Revenue from Contracts with Customers In January 2022, the Company began offering a subscription option to its customers, pursuant to which it leases its PrintRite3D platform for terms of between 12 and 36 months and provide technical support and maintenance for the term of the arrangement, as well as installation and training. The Company has determined these are leases because they relate to discrete pieces of equipment to which customers have the right to substantially all the economic benefit and exclusive right to use during the term of the arrangement. These leases are classified as operating leases and the Company retains title to the underlying equipment. The leases may be renewed for successive one-year terms unless notice is given by either party of its intent not to renew at least 30 days before the end of the lease term. For leases with 36-month terms, the lessee may terminate the agreement after the first 18 months upon at least 30 days written notice. Some, but not all, of the leases permit lessees to purchase the equipment at any time at an amount that approximates fair value and are not reasonably certain to be exercised at the inception of the lease. There are no anticipated variable lease payments at the inception of the lease. There are two non-lease components in the arrangement that consist of technical support and maintenance, and installation and training, respectively. The Company has elected single component practical expedient accounting to combine the technical support and maintenance with the lease as they have the same pattern of transfer. The installation and training component does not have the same pattern of transfer; therefore, this component is not eligible for single component practical expedient accounting. The consideration has been allocated on a relative fair value basis of the underlying lease and non-lease components. The Company has estimated the residual value of the leased equipment based on its useful life, and the ability to refurbish and sell the equipment, as well as the Company’s ability to componentize the hardware and utilize subassemblies in other products. Revenue from these operating leases for the three months ended March 31, 2023 was $ 17,006 Minimum Lease Payments Receivable Minimum lease payments receivable for the succeeding years ending December 31 are as follows: Schedule of Minimum Lease Payments Receivable Year ending December 31, Amount 2023 (remaining) $ 28,343 2024 8,503 2025 - 2026 - Thereafter - Total $ 36,846 Equipment Underlying Operating Leases: Equipment under operating leases as of March 31, 2023 was comprised of the following: Schedule of Assets underlying Operating Leases March 31, 2023 PrintRite 3D Hardware $ 77,208 Accumulated Depreciation (9,688 ) Net Book Value $ 67,520 The Company is depreciating the underlying equipment over its useful life of 7

Inventory

Inventory	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory	NOTE 2 – Inventory At March 31, 2023 and December 31, 2022, the Company’s inventory was comprised of the following: Schedule of Inventory March 31, 2023 December 31, 2022 Raw Materials $ 303,219 $ 294,194 Work in Process 212,649 140,723 Finished Goods 428,534 516,026 Total Inventory $ 944,402 $ 950,943

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 3 – Intangible Assets The Company’s intangible assets consist of patents and patent applications. The Company capitalizes costs incurred in connection with acquiring its patents. These costs include registration, documentation, and legal fees associated with the application. Costs incurred with patents that have been previously granted are expensed as incurred. Provisional patent applications are not amortized until a patent has been granted. Once a patent is granted, the Company will amortize the related costs over the estimated useful life of the patent. If a patent application is denied, then the costs will be expensed at that time. During the three months ended March 31, 2023, $ 5,130 The following is a summary of definite-life intangible assets less accumulated amortization as of March 31, 2023 and December 31, 2022, respectively: Summary of Definite-life Intangible Assets and Accumulated Amortization March 31, December 31, Provisional Patent Applications $ 717,812 $ 675,251 Patents 529,880 524,750 Less: Accumulated Amortization (82,134 ) (74,716 ) Net Intangible Assets $ 1,165,558 $ 1,125,285 Amortization expense on intangible assets was $ 7,418 4,978 The estimated aggregate amortization expense for years ending December 31 is as follows: Schedule of Aggregate Amortization Expense 2023 (Remaining) $ 22,404 2024 29,872 2025 29,872 2026 29,872 Thereafter 335,726 Intangible asset and amortization expense $ 447,746

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Equity	NOTE 4 - Stockholders’ Equity Common Stock In the first quarter of 2023, the Company issued 227,587 132 43,241 Also in the first quarter of 2023, the Company issued 2,428 17 655 Preferred Stock The Company is authorized to issue 10,000,000 0.001 316 465 In January 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors (the “Institutional Private Placement”), pursuant to which the Company issued and sold 1,640 1,000 9 0.58 On January 27, 2023, the holder of the remaining 132 270,828 At March 31, 2023, there were no Concurrent with the Institutional Private Placement, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued and sold to certain of its directors and the Company’s then largest stockholder 333 1,000 9 48,544 On January 23, 2023, the holder of 17 3,083 At March 31, 2023, 316 58,568 Stock Options The Company’s 2013 Equity Incentive Plan expired on March 15, 2023. As such, there were no On January 26, 2023, the Company granted options to its non-employee directors to purchase up to an aggregate of 52,380 0.58 25 75 On January 26, 2023, the Company granted 19 employees options to purchase up to an aggregate of 381,285 0.58 50 50 The Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s common stock on the grant date, but not less than 100% of the fair market value. Stock options are typically granted throughout the year and generally vest over a period from one to three years of service and expire five years from the grant date, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the vesting period for each stock option award. Total stock-based compensation expense included in the statements of operations for the three months ended March 31, 2023 and 2022 was $ 224,850 170,976 The fair value of stock-based awards was estimated using the Black-Scholes model with the following weighted average assumptions for the three months ended March 31, 2023 and 2022: Schedule of Share Based Payments Award Stock Options Valuation Assumptions 2023 2022 Dividend yield 0.0 % 0.00 % Risk-free interest rate 4.05 % 0.95 1.65 % Expected volatility 100.2 % 106.4 110.0 % Expected life (in years) 5 5 Option activity for the three months ended March 31, 2023 and the year ended December 31, 2022 was as follows: Schedule of Share Based Compensation Stock Option Activity Options Weighted Weighted Aggregate Options outstanding at December 31, 2021 1,395,882 4.24 3.89 - Granted 487,473 2.50 4.43 - Exercised - - - - Forfeited or cancelled (84,302 ) 4.39 - - Options outstanding at December 31, 2022 1,799,053 3.76 3.30 - Granted 433,665 0.58 4.83 - Exercised - - - - Forfeited or cancelled (170,059 ) 3.04 - - Options outstanding March 31, 2023 2,062,659 3.15 3.41 - Options expected to vest in the future as of March 31, 2023 555,378 1.99 4.16 - Options exercisable at March 31, 2023 1,507,281 3.58 3.14 - Options vested, exercisable, and options expected to vest at March 31, 2023 2,062,659 3.15 3.41 - The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the market price of our common stock for those awards that have an exercise price below the market price of our common stock. At March 31, 2023, no option had an exercise price below the $ 0.44 At March 31, 2023, there was $ 581,865 1.59 Stock Appreciation Rights On June 23, 2020, the board of directors (the “Board”) of the Company adopted the 2020 Stock Appreciation Rights Plan (the “Plan”). The purposes of the Plan are to: (i) enable the Company to attract and retain the types of employees, consultants, and directors (collectively, “Service Providers”) who will contribute to the Company’s long-range success; (ii) provide incentives that align the interests of Service Providers with those of the stockholders of the Company; and (iii) promote the success of the Company’s business. The Plan provides for incentive awards only in the form of stock appreciation rights payable in cash (“SARs”) and no shares of common stock are reserved or will be issued pursuant to the Plan. SARs may be granted to any Service Provider. A SAR is the right to receive an amount equal to the Spread with respect to a share of the Company’s common stock (“Share”) upon the exercise of the SAR. The “Spread” is the difference between the exercise price per share specified in a SAR agreement on the date of grant and the fair market value per share on the date of exercise of the SAR. The exercise price per share will not be less than 100% of the fair market value of a share of common stock on the date of grant of the SAR. The administrator of the Plan will have the authority to, among other things, prescribe the terms and conditions of each SAR, including, without limitation, the exercise price and vesting provisions, and to specify the provisions of the SAR Agreement relating to such grant. The Company did not grant any SAR’s during the three months ended March 31, 2023. The Company recognizes compensation expense and a corresponding liability for the fair value of the SARs over the vesting period for each SAR award. The SARs are revalued at each reporting date in accordance with ASC 718 “Compensation-Stock Compensation,” and any changes in fair value are reflected in the Statement of Operations as of the applicable reporting date. The fair value of SAR awards was estimated using the Black-Scholes model with the following weighted average assumptions for the three months ended March 31, 2023 and March 31, 2022: Schedule of Share Based Payments Award Stock Options Valuation Assumptions 2023 2022 Dividend yield - 0.00 % Risk-free interest rate - 0.82 1.65 % Expected volatility - 108.4 119.0 % Expected life (in years) - 5 SARs activity for the three months ended March 31, 2023 and the year ended December 31, 2022 was as follows: Schedule of Stock Option Activity Options Weighted Weighted Aggregate SARs outstanding at December 31, 2021 370,624 3.15 4.24 - Granted 814,862 1.81 4.48 - Exercised - - - - Forfeited or cancelled (27,699 ) 2.91 - - SARs outstanding at December 31, 2022 1,157,787 2.21 4.11 - Granted - - - - Exercised - - - - Forfeited or cancelled (166,156 ) 20.9 - - SARs outstanding March 31, 2023 991,631 2.23 3.86 - SARs expected to vest in the future as of March 31, 2023 688,864 2.01 4.02 - SARs exercisable at March 31, 2023 302,767 2.75 3.49 - SARs vested, exercisable, and SARs expected to vest at March 31, 2023 991,631 2.23 3.86 - The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the market price of our common stock for those awards that have an exercise price below the market price of our common stock. At March 31, 2023, no SAR had an exercise price below the $ 0.44 At March 31, 2023, there was $ 665,799 1.95 Warrants Warrant activity for the three months ended March 31, 2023 and the year ended December 31, 2022 was as follows: Schedule of Warranty Activity Warrants Weighted Weighted Warrants outstanding at December 31, 2021 3,987,931 6.10 2.10 Granted - - - Exercised - - - Forfeited or cancelled (164,652 ) - - Warrants outstanding at December 31, 2022 3,823,279 4.66 1.19 Granted 1,490,896 0.58 2.87 Exercised - - - Forfeited or cancelled - - - Warrants outstanding at March 31, 2023 5,314,175 3.19 1.48

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	NOTE 5 - Subsequent Events On April 13, 2023, The Nasdaq Stock Market (“Nasdaq”) notified us that although the Company’s common stock had not regained compliance with the minimum $1.00 bid price per share requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), the Nasdaq Staff has granted us an additional 180 calendar days, or until October 9, 2023, to regain compliance based on our meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the bid price requirement, and our intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. According to Nasdaq’s notice, if at any time during this additional time period the closing bid price of our common stock is at least $1 per share for a minimum of 10 consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. If we choose to implement a reverse stock split, it must be completed no later than ten business days prior to October 9, 2023 to regain compliance. If it appears to Nasdaq that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq will notify us that our common stock will be subject to delisting.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Basis of Presentation	Basis of Presentation
Going Concern	Going Concern The Company currently has sufficient cash and working capital to fund operations through June 2023 and will require additional funding in the public or private markets in the near-term to be able to continue operations. The Company currently has no understanding or agreement to obtain such funding, and there is no assurance that we will be successful in obtaining additional funding. If we fail to obtain sufficient funding when needed, we will be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations. As a result, there is substantial doubt about our ability to continue as a going concern.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company does not use derivative instruments for hedging market risk or for trading or speculative purposes.
Loss Per Share	Loss Per Share Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 March 31, 2023 2022 Warrants 5,314,175 3,825,781 Stock Options 2,062,659 1,547,797 Preferred Stock 58,568 148,918 Total Underlying Common Shares 7,435,402 5,522,496 The following table shows the amounts used in computing loss per share and the effect on net loss and the weighted average number of shares of dilutive potential common stock for the periods ended March 31, 2023 and 2022: Schedule of Computing Loss Per Share 2023 2022 Three Months Ended March 31 2023 2022 Net Loss per Common Share - Basic and Diluted $ (0.17 ) $ (0.21 ) Loss Applicable to Common Stockholders (numerator) $ (1,763,447 ) $ (2,221,615 ) Weighted Average Number of Common Shares Outstanding Used in Loss Per Share During the Period (denominator) 10,690,677 10,498,802
Accounting Estimates	Accounting Estimates
Leases	Leases
Long-Lived and Intangible Assets	Long-Lived and Intangible Assets
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers In January 2022, the Company began offering a subscription option to its customers, pursuant to which it leases its PrintRite3D platform for terms of between 12 and 36 months and provide technical support and maintenance for the term of the arrangement, as well as installation and training. The Company has determined these are leases because they relate to discrete pieces of equipment to which customers have the right to substantially all the economic benefit and exclusive right to use during the term of the arrangement. These leases are classified as operating leases and the Company retains title to the underlying equipment. The leases may be renewed for successive one-year terms unless notice is given by either party of its intent not to renew at least 30 days before the end of the lease term. For leases with 36-month terms, the lessee may terminate the agreement after the first 18 months upon at least 30 days written notice. Some, but not all, of the leases permit lessees to purchase the equipment at any time at an amount that approximates fair value and are not reasonably certain to be exercised at the inception of the lease. There are no anticipated variable lease payments at the inception of the lease. There are two non-lease components in the arrangement that consist of technical support and maintenance, and installation and training, respectively. The Company has elected single component practical expedient accounting to combine the technical support and maintenance with the lease as they have the same pattern of transfer. The installation and training component does not have the same pattern of transfer; therefore, this component is not eligible for single component practical expedient accounting. The consideration has been allocated on a relative fair value basis of the underlying lease and non-lease components. The Company has estimated the residual value of the leased equipment based on its useful life, and the ability to refurbish and sell the equipment, as well as the Company’s ability to componentize the hardware and utilize subassemblies in other products. Revenue from these operating leases for the three months ended March 31, 2023 was $ 17,006 Minimum Lease Payments Receivable Minimum lease payments receivable for the succeeding years ending December 31 are as follows: Schedule of Minimum Lease Payments Receivable Year ending December 31, Amount 2023 (remaining) $ 28,343 2024 8,503 2025 - 2026 - Thereafter - Total $ 36,846 Equipment Underlying Operating Leases: Equipment under operating leases as of March 31, 2023 was comprised of the following: Schedule of Assets underlying Operating Leases March 31, 2023 PrintRite 3D Hardware $ 77,208 Accumulated Depreciation (9,688 ) Net Book Value $ 67,520 The Company is depreciating the underlying equipment over its useful life of 7

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 March 31, 2023 2022 Warrants 5,314,175 3,825,781 Stock Options 2,062,659 1,547,797 Preferred Stock 58,568 148,918 Total Underlying Common Shares 7,435,402 5,522,496
Schedule of Computing Loss Per Share	The following table shows the amounts used in computing loss per share and the effect on net loss and the weighted average number of shares of dilutive potential common stock for the periods ended March 31, 2023 and 2022: Schedule of Computing Loss Per Share 2023 2022 Three Months Ended March 31 2023 2022 Net Loss per Common Share - Basic and Diluted $ (0.17 ) $ (0.21 ) Loss Applicable to Common Stockholders (numerator) $ (1,763,447 ) $ (2,221,615 ) Weighted Average Number of Common Shares Outstanding Used in Loss Per Share During the Period (denominator) 10,690,677 10,498,802
Schedule of Minimum Lease Payments Receivable	Minimum lease payments receivable for the succeeding years ending December 31 are as follows: Schedule of Minimum Lease Payments Receivable Year ending December 31, Amount 2023 (remaining) $ 28,343 2024 8,503 2025 - 2026 - Thereafter - Total $ 36,846
Schedule of Assets underlying Operating Leases	Equipment under operating leases as of March 31, 2023 was comprised of the following: Schedule of Assets underlying Operating Leases March 31, 2023 PrintRite 3D Hardware $ 77,208 Accumulated Depreciation (9,688 ) Net Book Value $ 67,520

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	At March 31, 2023 and December 31, 2022, the Company’s inventory was comprised of the following: Schedule of Inventory March 31, 2023 December 31, 2022 Raw Materials $ 303,219 $ 294,194 Work in Process 212,649 140,723 Finished Goods 428,534 516,026 Total Inventory $ 944,402 $ 950,943

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Definite-life Intangible Assets and Accumulated Amortization	The following is a summary of definite-life intangible assets less accumulated amortization as of March 31, 2023 and December 31, 2022, respectively: Summary of Definite-life Intangible Assets and Accumulated Amortization March 31, December 31, Provisional Patent Applications $ 717,812 $ 675,251 Patents 529,880 524,750 Less: Accumulated Amortization (82,134 ) (74,716 ) Net Intangible Assets $ 1,165,558 $ 1,125,285
Schedule of Aggregate Amortization Expense	The estimated aggregate amortization expense for years ending December 31 is as follows: Schedule of Aggregate Amortization Expense 2023 (Remaining) $ 22,404 2024 29,872 2025 29,872 2026 29,872 Thereafter 335,726 Intangible asset and amortization expense $ 447,746

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Share Based Payments Award Stock Options Valuation Assumptions	The fair value of stock-based awards was estimated using the Black-Scholes model with the following weighted average assumptions for the three months ended March 31, 2023 and 2022: Schedule of Share Based Payments Award Stock Options Valuation Assumptions 2023 2022 Dividend yield 0.0 % 0.00 % Risk-free interest rate 4.05 % 0.95 1.65 % Expected volatility 100.2 % 106.4 110.0 % Expected life (in years) 5 5
Schedule of Stock Option Activity	Option activity for the three months ended March 31, 2023 and the year ended December 31, 2022 was as follows: Schedule of Share Based Compensation Stock Option Activity Options Weighted Weighted Aggregate Options outstanding at December 31, 2021 1,395,882 4.24 3.89 - Granted 487,473 2.50 4.43 - Exercised - - - - Forfeited or cancelled (84,302 ) 4.39 - - Options outstanding at December 31, 2022 1,799,053 3.76 3.30 - Granted 433,665 0.58 4.83 - Exercised - - - - Forfeited or cancelled (170,059 ) 3.04 - - Options outstanding March 31, 2023 2,062,659 3.15 3.41 - Options expected to vest in the future as of March 31, 2023 555,378 1.99 4.16 - Options exercisable at March 31, 2023 1,507,281 3.58 3.14 - Options vested, exercisable, and options expected to vest at March 31, 2023 2,062,659 3.15 3.41 -
Schedule of Warranty Activity	Warrant activity for the three months ended March 31, 2023 and the year ended December 31, 2022 was as follows: Schedule of Warranty Activity Warrants Weighted Weighted Warrants outstanding at December 31, 2021 3,987,931 6.10 2.10 Granted - - - Exercised - - - Forfeited or cancelled (164,652 ) - - Warrants outstanding at December 31, 2022 3,823,279 4.66 1.19 Granted 1,490,896 0.58 2.87 Exercised - - - Forfeited or cancelled - - - Warrants outstanding at March 31, 2023 5,314,175 3.19 1.48
Stock Appreciation Rights [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Share Based Payments Award Stock Options Valuation Assumptions	The fair value of SAR awards was estimated using the Black-Scholes model with the following weighted average assumptions for the three months ended March 31, 2023 and March 31, 2022: Schedule of Share Based Payments Award Stock Options Valuation Assumptions 2023 2022 Dividend yield - 0.00 % Risk-free interest rate - 0.82 1.65 % Expected volatility - 108.4 119.0 % Expected life (in years) - 5
Schedule of Stock Option Activity	SARs activity for the three months ended March 31, 2023 and the year ended December 31, 2022 was as follows: Schedule of Stock Option Activity Options Weighted Weighted Aggregate SARs outstanding at December 31, 2021 370,624 3.15 4.24 - Granted 814,862 1.81 4.48 - Exercised - - - - Forfeited or cancelled (27,699 ) 2.91 - - SARs outstanding at December 31, 2022 1,157,787 2.21 4.11 - Granted - - - - Exercised - - - - Forfeited or cancelled (166,156 ) 20.9 - - SARs outstanding March 31, 2023 991,631 2.23 3.86 - SARs expected to vest in the future as of March 31, 2023 688,864 2.01 4.02 - SARs exercisable at March 31, 2023 302,767 2.75 3.49 - SARs vested, exercisable, and SARs expected to vest at March 31, 2023 991,631 2.23 3.86 -

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	7,435,402	5,522,496
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	5,314,175	3,825,781
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	2,062,659	1,547,797
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	58,568	148,918

Schedule of Computing Loss Per

Schedule of Computing Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounting Policies [Abstract]
Net Loss per Common Share - Basic and Diluted	$ (0.17)	$ (0.21)
Loss Applicable to Common Stockholders (numerator)	$ (1,763,447)	$ (2,221,615)
Weighted Average Number of Common Shares Outstanding Used in Loss Per Share During the Period (denominator)	10,690,677	10,498,802

Schedule of Minimum Lease Payme

Schedule of Minimum Lease Payments Receivable (Details)	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
2023 (remaining)	$ 28,343
2024	8,503
2025
2026
Thereafter
Total	$ 36,846

Schedule of Assets underlying O

Schedule of Assets underlying Operating Leases (Details)	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
PrintRite 3D Hardware	$ 77,208
Accumulated Depreciation	(9,688)
Net Book Value	$ 67,520

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Lease income from operating leases	$ 17,006
Underlying equipment useful life	7 years

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw Materials	$ 303,219	$ 294,194
Work in Process	212,649	140,723
Finished Goods	428,534	516,026
Total Inventory	$ 944,402	$ 950,943

Summary of Definite-life Intang

Summary of Definite-life Intangible Assets and Accumulated Amortization (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Less: Accumulated Amortization	$ (82,134)	$ (74,716)
Net Intangible Assets	1,165,558	1,125,285
Provisional Patent Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Patents	717,812	675,251
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Patents	$ 529,880	$ 524,750

Schedule of Aggregate Amortizat

Schedule of Aggregate Amortization Expense (Details)	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (Remaining)	$ 22,404
2024	29,872
2025	29,872
2026	29,872
Thereafter	335,726
Intangible asset and amortization expense	$ 447,746

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Amortization expense on intangible assets	$ 7,418	$ 4,978
Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Costs relate to patents issued	$ 5,130

Schedule of Share Based Payment

Schedule of Share Based Payments Award Stock Options Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend yield	0%	0%
Risk-free interest rate	4.05%
Risk-free interest rate, minimum		0.95%
Risk-free interest rate, maximum		1.65%
Expected volatility	100.20%
Expected volatility, minimum		106.40%
Expected volatility, maximum		110%
Expected life	5 years	5 years
2020 Stock Appreciation Rights Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend yield		0%
Risk-free interest rate
Risk-free interest rate, minimum		0.82%
Risk-free interest rate, maximum		1.65%
Expected volatility
Expected volatility, minimum		108.40%
Expected volatility, maximum		119%
Expected life		5 years

Schedule of Share Based Compens

Schedule of Share Based Compensation Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Number of Options, Outstanding, Beginning Balance	1,799,053	1,395,882
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 3.76	$ 4.24
Weighted Average Remaining Contractual Life Years, Outstanding Balance	3 years 4 months 28 days	3 years 3 months 18 days	3 years 10 months 20 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance
Number of Options, Granted	433,665	487,473
Weighted Average Exercise Price, Granted	$ 0.58	$ 2.50
Weighted Average Remaining Contractual Life Years, Granted	4 years 9 months 29 days	4 years 5 months 4 days
Aggregate Intrinsic Value, Granted
Number of Options, Exercised	0	0
Weighted Average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited or cancelled	(170,059)	(84,302)
Weighted Average Exercise Price, Forfeited or cancelled	$ 3.04	$ 4.39
Aggregate Intrinsic Value, Forfeited or cancelled
Number of Options, Outstanding, Outstanding Balance	2,062,659	1,799,053	1,395,882
Weighted Average Exercise Price, Outstanding Ending Balance	$ 3.15	$ 3.76	$ 4.24
Aggregate Intrinsic Value, Outstanding, Ending Balance
Number of Options, Expected to Vest in the Future Ending Balance	555,378
Weighted Average Exercise Price, Expected to Vest	$ 1.99
Weighted Average Remaining Contractual Life Years, Expected to Vest	4 years 1 month 28 days
Aggregate Intrinsic Value, Outstanding, Expected of Vest
Number of Options, Exercisable	1,507,281
Weighted Average Exercise Price, Exercisable	$ 3.58
Weighted Average Remaining Contractual Life Years, Exercisable	3 years 1 month 20 days
Aggregate Intrinsic Value, Outstanding, Exercisable
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	2,062,659
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 3.15
Weighted Average Remaining Contractual Life (Yrs.), Vested, Exercisable and Options Expected to Vest	3 years 4 months 28 days
Aggregate Intrinsic Value, Outstanding,Exercisable and Options Expected to Vest

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning Balance	1,799,053	1,395,882
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 3.76	$ 4.24
Weighted Average Remaining Contractual Life, Outstanding Balance	3 years 4 months 28 days	3 years 3 months 18 days	3 years 10 months 20 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance
Number of Options, Granted	433,665	487,473
Weighted Average Exercise Price, Granted	$ 0.58	$ 2.50
Aggregate Intrinsic Value, Granted
Number of Options, Exercised	0	0
Weighted Average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited or cancelled	(170,059)	(84,302)
Aggregate Intrinsic Value, Forfeited or cancelled
Number of Options, Outstanding, Outstanding Balance	2,062,659	1,799,053	1,395,882
Weighted Average Exercise Price, Outstanding Ending Balance	$ 3.15	$ 3.76	$ 4.24
Aggregate Intrinsic Value, Outstanding, Ending Balance
Number of Options, Expected to Vest in the Future Ending Balance	555,378
Weighted Average Exercise Price, Expected to Vest	$ 1.99
Weighted Average Remaining Contractual Life, Expected to Vest	4 years 1 month 28 days
Aggregate Intrinsic Value, Outstanding, Expected of Vest
Number of Options, Exercisable	1,507,281
Weighted Average Exercise Price, Exercisable	$ 3.58
Weighted Average Remaining Contractual Life, Exercisable	3 years 1 month 20 days
Aggregate Intrinsic Value, Outstanding, Exercisable
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	2,062,659
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 3.15
Weighted Average Remaining Contractual Life, Vested, Exercisable and Options Expected to Vest	3 years 4 months 28 days
Aggregate Intrinsic Value, Outstanding,Exercisable and Options Expected to Vest
Stock Appreciation Rights [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning Balance	1,157,787	370,624
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 2.21	$ 3.15
Weighted Average Remaining Contractual Life, Outstanding Balance	3 years 10 months 9 days	4 years 2 months 26 days	4 years 1 month 9 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance
Number of Options, Granted		814,862
Weighted Average Exercise Price, Granted		$ 1.81
Weighted Average Remaining Contractual Life, Granted		4 years 5 months 23 days
Aggregate Intrinsic Value, Granted
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited or cancelled	(166,156)	(27,699)
Weighted Average Exercise Price, Forfeited or cancelled	20 years 10 months 24 days	2 years 10 months 28 days
Aggregate Intrinsic Value, Forfeited or cancelled
Number of Options, Outstanding, Outstanding Balance	991,631	1,157,787	370,624
Weighted Average Exercise Price, Outstanding Ending Balance	$ 2.23	$ 2.21	$ 3.15
Aggregate Intrinsic Value, Outstanding, Ending Balance
Number of Options, Expected to Vest in the Future Ending Balance	688,864
Weighted Average Exercise Price, Expected to Vest	$ 2.01
Weighted Average Remaining Contractual Life, Expected to Vest	4 years 7 days
Aggregate Intrinsic Value, Outstanding, Expected of Vest
Number of Options, Exercisable	302,767
Weighted Average Exercise Price, Exercisable	$ 2.75
Weighted Average Remaining Contractual Life, Exercisable	3 years 5 months 26 days
Aggregate Intrinsic Value, Outstanding, Exercisable
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	991,631
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 2.23
Weighted Average Remaining Contractual Life, Vested, Exercisable and Options Expected to Vest	3 years 10 months 9 days
Aggregate Intrinsic Value, Outstanding,Exercisable and Options Expected to Vest

Schedule of Warranty Activity (

Schedule of Warranty Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Warrants Outstanding, Beginning Balance	3,823,279	3,987,931
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 4.66	$ 6.10
Weighted Average Remaining Contractual Life Years,Ending Balance	1 year 5 months 23 days	1 year 2 months 8 days	2 years 1 month 6 days
Warrants, Granted	1,490,896
Weighted Average Exercise Price Outstanding, Granted	$ 0.58
Weighted Average Remaining Contractual Life Years, Granted	2 years 10 months 13 days
Warrants,Exercised
Weighted Average Exercise Price Outstanding,Exercised
Warrants, Forfeited or cancelled		(164,652)
Weighted Average Exercise Price Outstanding, Forfeited or cancelled
Warrants Outstanding, Ending Balance	5,314,175	3,823,279	3,987,931
Weighted Average Exercise Price Outstanding,Ending Balance	$ 3.19	$ 4.66	$ 6.10

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 27, 2023	Jan. 26, 2023	Jan. 23, 2023	Jan. 31, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized					10,000,000		10,000,000
Preferred stock, par value					$ 0.001		$ 0.001
Preferred stock, shares outstanding					316		465
Preferred stock, shares issued					316		465
Options exercise price					$ 0.44
Number of shares granted					433,665		487,473
Allocation share based compensation expense					$ 224,850	$ 170,976
Unrecognized stock-based compensation expense, stock option					$ 581,865
Weighted average remaining recognition period					1 year 7 months 2 days
Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Vesting percentage					25%
Directors [Member] | December 31, 2022 [Member]
Subsidiary, Sale of Stock [Line Items]
Vesting percentage					75%
19 Employees [Member]
Subsidiary, Sale of Stock [Line Items]
Vesting percentage		50%
Number of shares granted		381,285
Option strike price		$ 0.58
2020 Stock Appreciation Rights Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Options exercise price					$ 0.44
Unrecognized share based compensation cost					$ 665,799
Weighted average remaining recognition period					1 year 11 months 12 days
Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Options exercise price		$ 0.58
Series D Convertible Preferred Stock [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of stock, shares converted					132
Number of shares as in-kind payment, shares					43,241
Series E Convertible Preferred Stock [Member] | Other Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of stock, shares converted					48,544
Share issued and sold during period, shares					333
Dividend rate					9%
Series E Convertible Preferred Stock [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of stock, shares converted					17
Number of shares as in-kind payment, shares					655
Series D Preferred Stock [Member] | Institutional Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock issued during period, shares	270,828
Preferred stock, par value				$ 1,000
Preferred stock, shares outstanding	132
Share issued and sold during period, shares				1,640
Dividend rate				9%
Conversion price per share				$ 0.58
Series E Preferred Stock [Member] | Institutional Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock issued during period, shares			3,083		58,568
Preferred stock, par value					$ 1,000
Preferred stock, shares outstanding			17		316
Private Placement [Member] | Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares of common stock		52,380
Private Placement [Member] | Series D Convertible Preferred Stock [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock issued during period, shares					227,587
Private Placement [Member] | Series E Convertible Preferred Stock [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock issued during period, shares					2,428